In summary, the present study demonstrates that reducing hepatic ApoA5 expression in mice by ASO treatment reduces LPL activity leading to hypertriglyceridemia and decreased lipid uptake by liver, muscle, and WAT. This evidence concerns the gene LPL and hypertriglyceridemia.